エピナスチン塩酸塩点眼液0.05％の点眼回数軽減の有効性

抄録

Purpose: To evaluate the efficacy of using 1 drop twice daily of epinastine hydrochloride ophthalmic solution 0.05% (epinastine eye drops) instead of the recommended 1 drop 4 times daily in patients with allergic conjunctivitis.

Subjects and Methods: Thirteen patients with subjective symptoms of allergic conjunctivitis who had not used epinastine eye drops and who visited our clinic in March and April 2017 were included in this study; they were instructed to use 1 drop twice daily. The subjective symptoms and objective findings before and after therapy were quantified at follow-up and statistically analyzed using the Wilcoxon signed-rank test. If improvement was insufficient with twice-daily administration, the dosing regimen was changed to 4 times daily.

Results: Excluding 1 subject who did not appear for the follow-up after initiation of therapy, the dose remained at twice daily in all 12 subjects. Itching was the only subjective symptom in all subjects. A comparison of subjective symptoms before and after therapy showed significant improvement in subjective symptoms (p<0.002) and objective findings (p<0.005) after therapy.

Conclusions: Reduced-dose therapy resulted in medication compliance. Since most children are not administered eye drops by school staff, twice-daily instillation enables parents to provide treatment at home.